Optimizing the Identification of HER2-Low Breast Cancer

Dr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.